WO2000030640A1 - Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia - Google Patents

Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia Download PDF

Info

Publication number
WO2000030640A1
WO2000030640A1 PCT/EP1999/009048 EP9909048W WO0030640A1 WO 2000030640 A1 WO2000030640 A1 WO 2000030640A1 EP 9909048 W EP9909048 W EP 9909048W WO 0030640 A1 WO0030640 A1 WO 0030640A1
Authority
WO
WIPO (PCT)
Prior art keywords
prucalopride
dyspeptic symptoms
use according
addition salt
pharmaceutically acceptable
Prior art date
Application number
PCT/EP1999/009048
Other languages
French (fr)
Inventor
Joannes Adrianus Jacobus Schuurkes
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP98203943 priority Critical
Priority to EP98203943.0 priority
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of WO2000030640A1 publication Critical patent/WO2000030640A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Abstract

The present invention is concerned with the use of prucalopride and pharmaceutically acceptable acid addition salts thereof for the manufacture of a medicament for the treatment of warm-blooded animals, including humans, suffering from dyspeptic symptoms.

Description

SE OF PRUCALOPRIDE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DYSPEPSIA

The present invention is concerned with the use of prucalopride and pharmaceutically acceptable acid addition salts thereof for the manufacture of a medicament for the treatment of warm-blooded animals, including humans, suffering from dyspeptic symptoms.

Prucalopride, which is the generic name for the (1 : 1) succinic acid addition salt of 4-amino-5-chloro-2,3-dihydro-N-[ 1 -(3-methoxypropyl)-4-piperidinyl]-7-benzofuran- carboxamide, has enterokinetic properties, i.e. it has strong gastrointestinal prokinetic activities.

Figure imgf000003_0001

Prucalopride facilitates both cholinergic and non-cholinergic non-adrenergic (NANC) excitatory neurotransmission and stimulates colonic motility and defecation in animals. It has no affinity for 5-HT2A and 5-HT3A receptors but is a potent and selective agonist of 5-HT4 receptors. Prucalopride induces giant contractions in the colon that are propagated over the length of the colon as a peristaltic wave and therefore has significant motility enhancing effects on the large intestine.

Prucalopride is generically described in EP-0,445,862-Al , published on 1 1 September

1991, and is specifically disclosed in WO-96/ 16060, published on 30 May 1996.

The term prucalopride as used herein comprises the free base form and the pharmaceutically acceptable acid addition salts thereof. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, /?-aminosalicylic, pamoic and the like acids. The term addition salt as used hereinabove also comprises the solvates which prucalopride as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like. Preferred pharmaceutically acceptable acid addition salts of 4-amino-5-chloro-2,3- dihydro-N-[ 1 -(3-methoxypropyl)-4-piperidinyl]-7-benzofuran-carboxamide are the hydrochloric acid (1 : 1) addition salt and the succinic acid (1: 1) addition salt.

In view of its enterokinetic properties, prucalopride is useful in the treatment of motility disorders of the intestinal system, such as, e.g. constipation, pseudo-obstruction, intestinal atony, post-operative intestinal atony, irritable bowel syndrome (IBS), and drug-induced delayed transit.

Unexpectedly, it was found that prucalopride is also useful to treat patients suffering from dyspeptic symptoms.

Dyspepsia, more commonly known as indigestion, is a very common disorder. In fact, between 15 to 20 percent of the population suffers from it on a recurring basis.

Dyspepsia can originate from a number of causes. For instance dyspeptic symptoms can be caused by a disturbed accommodation of food, hypersensitivity either peripherally or centrally mediated, disturbed gastric emptying, disturbed electrical rhythm, disturbed antro-duodenal coordination, or an impaired response to the intraluminal contents.

Recently it is also believed that in a number of patients suffering from dyspepsia, their dyspeptic symptoms may result from a decreased motility of the colon which keeps the colon in a more or less "filled" condition. It is believed that this feeling of a "full" colon or the feeling of pressure exerted on the stomach due to a filled colon can cause an "upset" stomach resulting in a number of dyspeptic symptoms. Said "full" colon may also cause a reflexive inhibition of the stomach resulting in dyspeptic symptoms.

Dyspeptic symptoms are for example a lack of appetite, feeling of fullness, early satiety, nausea, vomiting, bloating and gaseous eructation.

In view of the above described utility of prucalopride, it follows that the present invention also provides a method of treating warm-blooded animals, including humans, (generally called herein patients) suffering from dyspeptic symptoms such as, e.g. a lack of appetite, feeling of fullness, early satiety, nausea, vomiting, bloating and gaseous eructation. Consequently a method of treatment is provided for relieving patients suffering from dyspeptic symptoms, in particular dyspeptic symptoms caused by a decreased motility of the colon, by administering to said patients a therapeutically effective amount of prucalopride or a pharmaceutically acceptable acid addition salt thereof.

Hence, the present invention provides the use of prucalopride for the manufacture of a medicament for treating dyspeptic symptoms, in particular dyspeptic symptoms caused by a decreased motility of the colon. Both prophylactic and therapeutic treatment are envisaged.

To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

In general it is contemplated that a therapeutically effective amount would be from about 0.001 mg/kg to about 5 mg/kg body weight, preferably from about 0.01 mg/kg to about 0.5 mg/kg body weight. A method of treatment may also include administering the active ingredient on a regimen of between two or four intakes per day.

The amount of prucalopride. or a pharmaceutically acceptable acid addition salt thereof, required as daily dose in treatment will vary not only with the route of administration, the nature of the condition being treated and the age, weight and condition of the patient and will ultimately be at the discretion of the attendant physician. In general, however, a suitable daily dose will be in the range of from about 0.05 to about 200 mg per day, in particular from about 0.1 to 20 mg per day. more particular from about 0.5 to 10 mg per day. A suitable daily dose for use in prophylaxis will generally be in the same range. It may be appropriate to administer the required dose as two, three, four or more sub- doses at appropriate intervals throughout the day. Administration can be before or after the intake of food (i.e. preprandial or postprandial).

Experimental section.

The efficacy of prucalopride, or a pharmaceutically acceptable acid addition salt thereof, to treat subjects suffering from dyspeptic symptoms can be demonstrated by the following trial.

A group of healthy subjects is treated with an anti-diarrheal compound such as, e.g. loperamide, which causes a mild constipation in said subjects, i.e. the normal colon motility is reduced so that the subjects have a colon in a "filled" condition.

The group of subjects is split into a control group and a test group for treatment with prucalopride. The subjects in the test group are then treated with prucalopride.

Then, the subjects in both groups are served a standard breakfast consisting of four slices of bread, one slice of ham, one slice of cheese, butter, jelly and two cups of coffee or tea with, if desired, milk and/or sugar. The number of subjects suffering from dyspeptic symptoms and the seriousness of the dyspeptic symptoms are recorded and compared between the test group and the control group.

The above described trial can be modified by treating the test group with prucalopride after the subjects have finished their meal. The trial can be done open, or blindfolded, using a randomized group of subjects.

Alternatively, out of a group of subjects suffering from dyspeptic symptoms, a sub-group of subjects can be selected also having reduced colon motility. Said sub-group can be given prucalopride, or a pharmaceutically acceptable acid addition salt thereof, either preprandial or postprandial and the reduction of the number or seriousness of the dyspeptic symptoms can be recorded.

Conversely, out of a group of subjects suffering from reduced colon motility, and therefore having a reduced stool frequency, a sub-group of subjects can be selected also having dyspeptic symptoms. Said sub-group can be given prucalopride, or a pharmaceutically acceptable acid addition salt thereof, either preprandial or postprandial and the reduction of the number or seriousness of the dyspeptic symptoms can be recorded.

Claims

Claims
1. Use of prucalopride or a pharmaceutically acceptable addition salt thereof for the manufacture of a medicament for the treatment of patients having dyspeptic symptoms.
2. Use according to claim 1 wherein the dyspeptic symptoms are caused by a decreased motility of the colon.
3. Use according to any of claims 1 to 2 wherein the pharmaceutically acceptable addition salt of prucalopride is the (1 : 1 ) succinic acid addition salt.
4. Use according to any of claims 1 to 3 wherein the dyspeptic symptoms comprise lack of appetite.
5. Use according to any of claims 1 to 3 wherein the dyspeptic symptoms comprise the feeling of fullness.
6. Use according to any of claims 1 to 3 wherein the dyspeptic symptoms comprise early satiety.
7. Use according to any of claims 1 to 3 wherein the dyspeptic symptoms comprise nausea and vomiting.
8. Use according to any of claims 1 to 3 wherein the dyspeptic symptoms comprise bloating or gaseous eructation.
9. Use according to any of claims 1 to 3 wherein the daily dose of prucalopride or a pharmaceutically acceptable addition salt thereof ranges from 0.05 mg to 200 mg per day.
10. Use according to claim 9 wherein the daily dose ranges from 0.1 mg to 20 mg per day.
PCT/EP1999/009048 1998-11-23 1999-11-16 Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia WO2000030640A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP98203943 1998-11-23
EP98203943.0 1998-11-23

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AU13857/00A AU770580B2 (en) 1998-11-23 1999-11-16 Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia
CA002352278A CA2352278A1 (en) 1998-11-23 1999-11-16 Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia
NZ511117A NZ511117A (en) 1998-11-23 1999-11-16 Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia
KR1020017004376A KR20010080025A (en) 1998-11-23 1999-11-16 Use of Prucalopride for the Manufacture of a Medicament for the Treatment of Dyspepsia
EP99972536A EP1135130A1 (en) 1998-11-23 1999-11-16 Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia
JP2000583523A JP2002530334A (en) 1998-11-23 1999-11-16 Use of prucalopride for the manufacture of a medicament for the treatment of indigestion

Publications (1)

Publication Number Publication Date
WO2000030640A1 true WO2000030640A1 (en) 2000-06-02

Family

ID=8234369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/009048 WO2000030640A1 (en) 1998-11-23 1999-11-16 Use of prucalopride for the manufacture of a medicament for the treatment of dyspepsia

Country Status (7)

Country Link
EP (1) EP1135130A1 (en)
JP (1) JP2002530334A (en)
KR (1) KR20010080025A (en)
AU (1) AU770580B2 (en)
CA (1) CA2352278A1 (en)
NZ (1) NZ511117A (en)
WO (1) WO2000030640A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066170A1 (en) * 1999-04-29 2000-11-09 Janssen Pharmaceutica N.V. Prucalopride oral solution
WO2003059906A1 (en) * 2002-01-16 2003-07-24 Janssen Pharmaceutica N.V. Prucalopride-n-oxide
EP1493441A1 (en) * 2002-04-08 2005-01-05 Zeria Pharmaceutical Co., Ltd. Therapeutic agent for food competence disorder in stomach

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389037A1 (en) * 1989-03-22 1990-09-26 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
EP0445862A2 (en) * 1990-03-06 1991-09-11 Janssen Pharmaceutica N.V. N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives
WO1996016060A1 (en) * 1994-11-24 1996-05-30 Janssen Pharmaceutica N.V. Enterokinetic benzamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0389037A1 (en) * 1989-03-22 1990-09-26 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
EP0445862A2 (en) * 1990-03-06 1991-09-11 Janssen Pharmaceutica N.V. N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives
WO1996016060A1 (en) * 1994-11-24 1996-05-30 Janssen Pharmaceutica N.V. Enterokinetic benzamide

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066170A1 (en) * 1999-04-29 2000-11-09 Janssen Pharmaceutica N.V. Prucalopride oral solution
US6413988B1 (en) 1999-04-29 2002-07-02 Janssen Pharmaceutica N.V. Prucalopride oral solution
JP2002543161A (en) * 1999-04-29 2002-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Prucalopride oral solution
MY119880A (en) * 1999-04-29 2005-07-29 Janssen Pharmaceutica Nv Prucalopride oral solution
HRP20010764B1 (en) * 1999-04-29 2011-01-31 Janssen Pharmaceutica N.V. Prucalopride oral solution
JP4773619B2 (en) * 1999-04-29 2011-09-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap Purcarapride oral solution
WO2003059906A1 (en) * 2002-01-16 2003-07-24 Janssen Pharmaceutica N.V. Prucalopride-n-oxide
US8063069B2 (en) 2002-01-16 2011-11-22 Janssen Pharmaceutica N.V. Prucalopride-N-oxide
EP1493441A1 (en) * 2002-04-08 2005-01-05 Zeria Pharmaceutical Co., Ltd. Therapeutic agent for food competence disorder in stomach
EP1493441A4 (en) * 2002-04-08 2007-10-17 Zeria Pharm Co Ltd Therapeutic agent for food competence disorder in stomach

Also Published As

Publication number Publication date
KR20010080025A (en) 2001-08-22
EP1135130A1 (en) 2001-09-26
JP2002530334A (en) 2002-09-17
CA2352278A1 (en) 2000-06-02
AU770580B2 (en) 2004-02-26
AU1385700A (en) 2000-06-13
NZ511117A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
US20170312269A1 (en) Compositions and methods for reducing food cravings
US8679549B2 (en) Electrolyte purgative
AU781827B2 (en) Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
AU2001100681A4 (en) Extracts of magnoliaceae plants and their use as anxiolytic and sedative agent
EP1438957B1 (en) Raloxifene in the treatment of postmenopausal osteoporosis
TWI314053B (en) Use of compounds that are effective as selective opiate receptor modulators
US6444665B1 (en) Method for treating pain
Rabine et al. Management of the patient with gastroparesis
US4316888A (en) Method and composition of reducing pain
ES2144980T3 (en) Compositions to treat allergy rhinitis and other discarboetoxyloratadine disorders.
CN1080118C (en) Freeze-dried ondanstetron compositions
DE69828881T2 (en) Composition to treat disorders of human health in healthy individuals
AU720582B2 (en) Immediate release PH-independent solid dosage form of cisapride
US5593685A (en) Ranitidine compositions
EP2826475B1 (en) Trans-clomiphene for treating diabetes in hypogonadal men
US6737400B2 (en) Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
DE69837473T2 (en) Use of antagonists of central cannabinoid receptors for regulating sexhirts
US7192966B2 (en) Pharmaceutical composition
DE69924375T2 (en) Use of optically pure (+) - norcisapride for the treatment of reizdary syndrome
DE69633016T2 (en) Optically pure (-) norcisaprid for treating diseases of the digestive tract
JP4445590B2 (en) Oral liquid composition containing paroxetine-resin
CN1124134C (en) Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, ihibitor of macrophage-lipid complex accumulation on the arterial wall and preventive agent
EP0853480B1 (en) Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels
KR100877600B1 (en) Pharmaceutical composition comprising metadoxine and garlic oil for preventing and treating alcohol-induced fatty liver and steatohepatitis
US20140221434A1 (en) Altering pharmacokinetics of pirfenidone therapy

Legal Events

Date Code Title Description
ENP Entry into the national phase in:

Ref country code: AU

Ref document number: 2000 13857

Kind code of ref document: A

Format of ref document f/p: F

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999972536

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020017004376

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 511117

Country of ref document: NZ

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 583523

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09856436

Country of ref document: US

ENP Entry into the national phase in:

Ref document number: 2352278

Country of ref document: CA

Ref country code: CA

Ref document number: 2352278

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 13857/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020017004376

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999972536

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999972536

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 13857/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020017004376

Country of ref document: KR